3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
29
Neoplasms
4
Renal Insufficiency
3
Recurrence
3
Neoplasms, Plasma Cell
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Paraproteinemias
2
Neoplasms by Histologic Type
2
Immunoglobulin Light-chain Amyloidosis
2
Blood Protein Disorders
2
Purpura
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Hepatomegaly
1
Hematologic Neoplasms
1
Gastrointestinal Hemorrhage
1
Diarrhea
1
Interventions
Cyclophosphamide
192
Methotrexate
106
Cytarabine
86
fludarabine phosphate
80
Busulfan
71
Tacrolimus
70
Peripheral Blood Stem Cell Transplantation
69
Mycophenolic Acid
69
Whole-Body Irradiation
68
Vincristine
67
fludarabine
61
Filgrastim
61
Etoposide
59
Dexamethasone
54
Melphalan
52
Radiotherapy
47
Rituximab
46
Cyclosporine
46
Doxorubicin
38
Antilymphocyte Serum
37
Thiotepa
35
Granulocyte Colony-Stimulating Factor
35
Prednisone
34
Mercaptopurine
34
blinatumomab
33
pegaspargase
27
Methylprednisolone
27
Daunorubicin
26
Clofarabine
26
Asparaginase
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
isatuximab
×
Clear all
NCT03860844
2025-09-09
ISAKIDS
Sanofi
Phase 2
Terminated
67 enrolled
25 charts